Menu
← Oncology Approval Tracker
FDA DECISION ·
Koselugo
selumetinib · AstraZeneca Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Oral granules and capsules for children age 1 year or older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
LAMPGEN ANALYSIS
Why it matters
Exposure data bridged the new granules to capsules and supported extending treatment of these benign tumors to age 1.
What research teams should watch
Train caregivers in formulation-specific preparation and check body surface area, ocular monitoring, and medication handling.
PRIMARY RECORDS